Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis Highlights Growth To $2.36 Billion By 2030 At 6.2% CAGR

The chemotherapy induced peripheral neuropathy (CIPN) treatment market is positioned for substantial growth in the coming years, driven by advancements in targeted therapies and personalized oncology care. As the need for effective management of chemotherapy side effects rises, this market is attracting significant attention from pharmaceutical companies and researchers alike. Let's explore the current market size, growth factors, leading players, and emerging trends shaping this important healthcare segment.

Projected Market Growth and Size of the Chemotherapy Induced Peripheral Neuropathy Treatment Market
The CIPN treatment market is anticipated to reach a valuation of $2.37 billion by 2030, growing steadily at a compound annual growth rate (CAGR) of 6.2%. This expansion is largely fueled by increased investments in targeted neuropathy therapies, an emphasis on personalized supportive oncology treatments, and a surge in clinical trials focused on new CIPN drugs. Additionally, advancements in biomarker-based diagnosis and a growing demand for therapies that improve patients' quality of life are expected to further accelerate growth during the forecast period. Key market trends include heightened efforts in neuroprotective drug development, wider adoption of combination therapy strategies, early diagnosis and symptom management improvements, personalized treatment protocols, and expanding clinical research into CIPN management.

The chemotherapy induced peripheral neuropathy treatment market size has grown strongly in recent years. It will grow from $1.75 billion in 2025 to $1.86 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing use of neurotoxic chemotherapy agents, rising cancer survival rates, growing recognition of chemotherapy side effects, availability of symptomatic treatment options, expansion of oncology care infrastructure.

Download a free sample of the chemotherapy induced peripheral neuropathy treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Fueling Growth in the Chemotherapy Induced Peripheral Neuropathy Treatment Market
Rising investments in innovative neuropathy treatment options are a primary driver for market expansion. Pharmaceutical companies are increasingly allocating resources to develop drugs that target the underlying causes of CIPN, aiming to offer more effective and less toxic alternatives for patients undergoing chemotherapy.
Alongside this, there is a growing importance placed on personalized oncology care, which tailors supportive treatments to individual patient needs. This approach not only enhances treatment efficacy but also helps manage adverse effects better, improving overall patient outcomes and quality of life.

Prominent Companies Leading the Chemotherapy Induced Peripheral Neuropathy Treatment Market
The CIPN treatment landscape is shaped by several influential players, including Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., and Apollo Endosurgery Inc.

View the full chemotherapy induced peripheral neuropathy treatment market report:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Strategic Acquisition Highlighting Market Expansion
In a notable development in August 2024, Pharmacosmos Group, an international healthcare company based in Denmark, acquired G1 Therapeutics for $405 million. This strategic acquisition aims to broaden and expedite the availability of COSELA (trilaciclib), a treatment designed to reduce chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). G1 Therapeutics, headquartered in the US, specializes in developing and commercializing small molecule therapies targeting cancer patients, enhancing Pharmacosmos' oncology portfolio.

Current Trends Shaping the Chemotherapy Induced Peripheral Neuropathy Treatment Industry
Leading companies in the CIPN treatment market are actively focusing on innovation to strengthen their market position. For instance, in March 2023, AlgoTx, a clinical-stage firm specializing in complex pain management, announced FDA approval of the Investigational New Drug Application (IND) for ATX01, a Phase 2 first-in-class candidate targeting erythromelalgia.
Meanwhile, the initial patients in the ATX01 for the Pain of Chemotherapy (ACT) study for chemotherapy-induced peripheral neuropathy have been randomized. Both these programs have been granted fast-track designation by the FDA, underscoring the urgency and high potential of these treatments.

Detailed Segmentation of the Chemotherapy Induced Peripheral Neuropathy Treatment Market
This market is systematically divided into key segments to better understand its components:
1) Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, and Other Drug Classes
2) Treatment Type: Medication, Therapy, Other Treatments
3) Drug Type: Branded and Generic
4) Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Other Distribution Channels
5) End-User: Hospitals, Research Institutes, Specialty Clinics

Further Breakdown of Drug Classes
Within nerve protective therapies, specific drugs include Vitamin B Complex, Alpha-Lipoic Acid, and Acetyl-L-Carnitine. Anti-inflammatory therapies cover corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs). Neurotransmitter based therapies feature medications such as Gabapentin, Pregabalin, and Duloxetine. Antioxidant treatments involve N-acetylcysteine, Glutathione, and Coenzyme Q10. Other drug categories encompass topical treatments, opioids, and herbal remedies, providing a broad spectrum of therapeutic approaches for CIPN management.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.